Trials / Recruiting
RecruitingNCT06840002
A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer
An Open, Multicenter Phase Ib / II Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer
- Status
- Recruiting
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 150 (estimated)
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Industry
- Sex
- Female
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The objective is to evaluate the tolerance, safety, pharmacokinetic characteristics and immunogenicity of SHR-A1811 combined with carboplatin and bevacizumab in the treatment of platinum sensitive recurrent epithelial ovarian cancer, and to determine the RP2D of the combination, and preliminarily to evaluate the effectiveness of SHR-A1811 combined regimen in the treatment of platinum sensitive recurrent epithelial ovarian cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-A1811 | SHR-A1811. |
| DRUG | Carboplatin | Carboplatin. |
| DRUG | Bevacizumab | Bevacizumab. |
| DRUG | Oxaliplatin for Injection | Oxaliplatin for injection. |
| DRUG | Paclitaxel injection | Paclitaxel injection. |
| DRUG | Doxorubicin hydrochloride liposome injection | Doxorubicin hydrochloride liposome injetction. |
| DRUG | Adebrelimab Injection | Adebrelimab injection. |
Timeline
- Start date
- 2025-03-18
- Primary completion
- 2026-05-01
- Completion
- 2026-07-01
- First posted
- 2025-02-21
- Last updated
- 2025-09-30
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06840002. Inclusion in this directory is not an endorsement.